Artificial intelligence for aging and longevity research: Recent advances and perspectives.

Aging biomarker Artificial intelligence Deep learning Drug discovery Generative adversarial networks Metalearning Reinforcement learning Symbolic learning

Journal

Ageing research reviews
ISSN: 1872-9649
Titre abrégé: Ageing Res Rev
Pays: England
ID NLM: 101128963

Informations de publication

Date de publication:
01 2019
Historique:
received: 29 09 2018
revised: 07 11 2018
accepted: 21 11 2018
pubmed: 26 11 2018
medline: 21 1 2020
entrez: 26 11 2018
Statut: ppublish

Résumé

The applications of modern artificial intelligence (AI) algorithms within the field of aging research offer tremendous opportunities. Aging is an almost universal unifying feature possessed by all living organisms, tissues, and cells. Modern deep learning techniques used to develop age predictors offer new possibilities for formerly incompatible dynamic and static data types. AI biomarkers of aging enable a holistic view of biological processes and allow for novel methods for building causal models-extracting the most important features and identifying biological targets and mechanisms. Recent developments in generative adversarial networks (GANs) and reinforcement learning (RL) permit the generation of diverse synthetic molecular and patient data, identification of novel biological targets, and generation of novel molecular compounds with desired properties and geroprotectors. These novel techniques can be combined into a unified, seamless end-to-end biomarker development, target identification, drug discovery and real world evidence pipeline that may help accelerate and improve pharmaceutical research and development practices. Modern AI is therefore expected to contribute to the credibility and prominence of longevity biotechnology in the healthcare and pharmaceutical industry, and to the convergence of countless areas of research.

Identifiants

pubmed: 30472217
pii: S1568-1637(18)30240-X
doi: 10.1016/j.arr.2018.11.003
pii:
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

49-66

Informations de copyright

Copyright © 2018 The Authors. Published by Elsevier B.V. All rights reserved.

Auteurs

Alex Zhavoronkov (A)

Pharmaceutical Artificial Intelligence Department, Insilico Medicine, Inc., Baltimore, MD, United States; Biogerontology Research Foundation, London, United Kingdom; Buck Institute for Research on Aging, Novato, CA, United States.

Polina Mamoshina (P)

Pharmaceutical Artificial Intelligence Department, Insilico Medicine, Inc., Baltimore, MD, United States; Department of Computer Science, University of Oxford, Oxford, United Kingdom.

Quentin Vanhaelen (Q)

Pharmaceutical Artificial Intelligence Department, Insilico Medicine, Inc., Baltimore, MD, United States. Electronic address: vanhaelen@insilicomedicine.com.

Morten Scheibye-Knudsen (M)

Center for Healthy Aging, Department of Cellular and Molecular Medicine, University of Copenhagen, Denmark.

Alexey Moskalev (A)

George Mason University, Fairfax, VA, United States.

Alex Aliper (A)

Pharmaceutical Artificial Intelligence Department, Insilico Medicine, Inc., Baltimore, MD, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH